newsfilter
← Latest News
GlobeNewswire·

Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program

– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th International Congress on Autoimmunity being he